Factor VIIa for severe cardiac surgical bleeding
© BioMed Central Ltd 2002
Published: 9 July 2002
Severe perioperative bleeding in cardiac surgery is multifactorial in origin. Recombinant factor VIIa (rFVIIa; Novo Nordisk, Denmark) has been used perioperatively since 1988 . It promotes formation of blood clots by a range of actions. We have recently introduced it into our cardiac surgical programme for severe intractable coagulopathic bleeding.
Purpose of study
To assess efficacy and safety of rFVIIa in cardiac surgery by chart review.
Charts for the seven patients who received rFVIIa were reviewed for effects on clinical status, blood loss and transfusion need.
Median units of blood product used for the five surviving patients (range)
Fresh frozen plasma
There have been two published reports on the use of rFVIIa in cardiac surgery involving one and five patients, respectively [2,3]. In this review, we have found that five out of seven patients all with severe perioperative bleeding appeared to benefit from the administration of rFVIIa. There were no thrombotic complications noted. Further research into the optimal role for rFVIIa in cardiac surgery is justified.
- Hedner U, Glazer S, Pingel K, et al.: Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy [letter]. Lancet 1988, 2: 1193. 10.1016/S0140-6736(88)90259-0View ArticlePubMedGoogle Scholar
- Hendriks HG, van der Maaten JM, de Wolf J, et al.: An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001, 93: 287-289. 10.1097/00000539-200108000-00009PubMedGoogle Scholar
- Al Douri M, Shafi T, Al Khudairi D, et al.: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000,11(suppl 1):S121-S127.View ArticlePubMedGoogle Scholar